Since the publication of the previous edition of this volume, there has been substantial progress in a number of areas of multiple sclerosis (MS) research. Although immunosuppressive treatments continue to be developed and refined, more targeted immunomodulatory therapies are surfacing as we learn more about how the immune system works in health and disease. Multiple Sclerosis Therapeutics, Third Edition provides a comprehensive review of clinical trial methodology and therapeutic modalities in MS. This edition reflects current understanding of the pathophysiology of the disease and includes popular and emerging treatments. Topics include: Biomarkers in MS Pharmacogenomics Emerging therapeutic modalities such as natalizumab, T-cell-based and B-cell-based therapies, cytokine/chemokine-based therapies, statins, and 4-aminopyridine Neuroprotection The use of OCT and MRI to guide disease therapy Within the next several years, we will begin to discover the utility and the limitations of stem cells in the treatment of MS. It is likely that the next edition of this text will include clinical trial data that evaluate early attempts at nervous system regeneration in MS. Until that time occurs, this volume remains an essential resource for neurologists and anyone involved in the treatment of MS.Milan: SpringerVerlag, 1999: 145a67 Alfano B, Brunetti A, Larobina M, et al. Automated segmentation and ... The variability of manual and computer assisted quantification of multiple sclerosis lesion volumes. Med Phys 1996; 23: 85a97anbsp;...
|Title||:||Multiple Sclerosis Therapeutics, Third Edition|
|Author||:||Jeffrey A. Cohen, Richard A. Rudick|
|Publisher||:||CRC Press - 2007-03-06|